Potrero Hill Therapeutics

Potrero Hill Therapeutics is a private, preclinical-stage biotech leveraging the expertise of its founding team to identify and develop novel therapeutics in oncology and immunology. The company's model is built on selecting programs with addressable markets, valid science, and clear regulatory precedent to de-risk development and drive toward clinical proof-of-concept. With a focus on capital efficiency and IP creation, PHT aims to generate value through early-stage exits, though it faces risks typical of preclinical biotechs, including pipeline dependency and funding needs.

Experienced-based drug development methodology focused on evaluating and advancing preclinical opportunities with addressable markets, valid science, and clear regulatory precedent. No proprietary technological platform disclosed.

PHT operates in the highly competitive oncology and immunology sectors, competing with hundreds of biotechs and large pharma companies. Its success will depend on identifying novel angles or superior compounds within crowded target classes or discovering new biology, all while managing resources more efficiently than better-funded rivals.